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ABSTRACT: A 3-pyridyl ether scaffold bearing a cyclopropane-
containing side chain was recently identified in our efforts to
create novel antidepressants that act as partial agonists at α4β2-
nicotinic acetylcholine receptors. In this study, a systematic
structure−activity relationship investigation was carried out on
both the azetidine moiety present in compound 3 and its right-
hand side chain, thereby discovering a variety of novel nicotinic
ligands that retain bioactivity and feature improved chemical stability. The most promising compounds, 24, 26, and 30,
demonstrated comparable or enhanced pharmacological profiles compared to the parent compound 4, and the N-
methylpyrrolidine analogue 26 also exhibited robust antidepressant-like efficacy in the mouse forced swim test. The favorable
ADMET profile and chemical stability of 26 further indicate this compound to be a promising lead as a drug candidate
warranting further advancement down the drug discovery pipeline.
■ INTRODUCTION
Neuronal nicotinic acetylcholine receptors (nAChRs) belong to
the ligand-gated ion channel superfamily of neurotransmitter
receptors, which are widely distributed in the central and
peripheral nervous system.1 They are thought to be vital players
modulating major brain functions and participating in
pathophysiological processes, and the dysfunction of this family
of receptors has been implicated in a variety of nervous system
disorders such as Alzheimer’s disease, Parkinson’s disease,
schizophrenia, nicotine addiction, and depression.1 Brain
nAChRs are homomeric or heteromeric pentamers assembled
from diverse combinations of subunits (α2−α10 and β2−β4),
and different subtype stoichiometries allow the assembly of
varied pentamers with a wide range of physiological and
pharmacological profiles.2 Increasing evidence has implied that
the α4β2*-nAChRs (the asterisk denotes the possible
integration of other subunits aside from those specified into
the pentamer), the most abundant and widespread nAChRs in
the brain, may play a role in mood and reward. Numerous
preclinical studies in murine models have illustrated that
administration of α4β2-nAChR partial agonists or antagonists
potentiates antidepressant-like effects of conventional anti-
depressants, suggesting possible human use as an adjunctive
therapy, but also indicate that nicotinic ligands acting alone can
elicit antidepressant-like effects.3 The antidepressant effects of
mecamylamine, and even those of the tricyclic antidepressant
amitriptyline, are abolished in nAChR β2 subunit knockout
mice that lack α4β2*-nAChRs.4,5 Moreover, results of clinical
trials in depressed patients also demonstrate that the marketed
drug varenicline, an α4β2-nAChR partial agonist for smoking
cessation pharmacotherapy, has positive effects on relieving the
symptoms of depression.6 Given that more than one-third of
depressed individuals are resistant to currently available drug
treatments,7 selective α4β2-nAChR ligands could offer hope as
mechanistically novel antidepressant medications. In addition,
considerable progress has recently been made in understanding
nAChRs containing the α6 subunit regarding their anatomical
distribution, subunit composition, and physiological function.
Although their expression in the brain is relatively restricted,
these receptors are prevalent in midbrain dopaminergic regions
and are thought to influence physiological mechanisms
associated with mood and drug dependence.8,9
Azetidine is a four-membered nitrogen-containing saturated
heterocycle possessing reasonable chemical stability. With the
increasing number of methods that have been developed for the
synthesis of four-membered ring systems,10 azetidine-contain-
ing building blocks have received considerable interest by the
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medicinal chemistry community as components in various
drugs or bioactive compounds. For instance, azetidine-2-one
(β-lactam ring) is the key structural element of β-lactam
antibiotics that were discovered more than 80 years ago and are
still widely used clinically, as exemplified by penicillins,
cephalosporins, and pemems.11 Azelnidipine, a long-acting
calcium channel blocker containing a azetidinyl ether unit, has
been approved in Japan as an antihypertensive drug.12
Additionally, the azetidine moiety has also been introduced
by Abbott laboratories for the development of neuronal nAChR
ligands for treating specific CNS disorders with reduced side
effect liabilities.13 Among them, tebanicline (1) is a highly
potent α4β2-nAChR agonist with improved selectivity over
other subtypes in comparison with the parent compound
epibatidine (2). A chiral azetidinylmethoxy group was used to
replace the 7-azabicyclo[2.2.1]heptane structure in compound
2, providing a protonated nitrogen atom as an essential
pharmacophoric element of nicotinic ligands (Figure 1).
Although compound 1 was abandoned after completing
phase II clinical trials for the treatment of neuropathic pain
due to an unacceptably narrow therapeutic index,14 the 3-
pyridyl ether scaffold offers new perspectives on the design of
α4β2-nAChR ligands and holds promise for α4β2-nAChR
modulators to be advanced to the clinic as novel therapeutic
agents.
Previously, in our efforts to design nAChR ligands as
potential antidepressants, a series of selective α4β2-nAChR
partial agonists were identified based on the 3-pyridyl ether
scaffold.15 The chiral cyclopropane-containing side chain
appended to the 5-position of the pyridine ring confers
substantial nAChR subtype selectivity to these ligands
compared to the 5-unsubstituted compound A-85380, partic-
ularly over ganglionic α3β4*-nAChRs that are thought to be
associated with unwanted side effects in vivo16 while not
affecting their high affinity for α4β2-nAChRs. Some of the most
promising compounds (3 and 4) demonstrate favorable
antidepressant-like effects in the mouse forced swim test as
well as acceptable ADMET profiles and may thus serve as
suitable lead compounds for the development of novel
antidepressant agents. However, it is noteworthy that the
hydrochloride salt of compound 3 was hygroscopic and
partially decomposed after the absorption of water to give
considerable quantities of a major byproduct. On the basis of
analysis of LC-MS results and NMR spectra, the structure of
the decomposition product was identified as a dimer of the
parent compound, which resulted from attack of one azetidine
nitrogen atom on the less-substituted α-methylene group of
another azetidine ring. Similar intermolecular dimerization was
also observed by Abbott chemists during the process of salt
screening and selection for compound 1.17 Although this
potential stability issue can be prevented by changing the salt
form of these azetidine-containing ligands,17 replacement of the
azetidine unit by other ring systems having improved chemical
stability is a logical first choice. Thus, in continuation of our
efforts to develop α4β2-nAChR ligands for treating depression,
a novel series of nAChR ligands with different ring systems
replacing the azetidine ring found in the lead compound 4 were
designed and synthesized for pharmacological evaluation.
Selected compounds were further assessed in behavioral tests
used to gauge antidepressant drug action, and preliminary
ADMET studies were carried out. Moreover, we detailed
additional structural modifications of the side chain attached to
the 5-position of the pyridine ring.
■ CHEMISTRY
In our previous study of the isoxazolylpyridine ether analogues,
we found that the length of the side chain was crucial to their
biological activity.18 We thus chose to synthesize cyclopropane
ligands bearing a shorter or longer side chain in comparison
with compound 3 to explore the optimal length of the side
chain for the cyclopropane series. In addition, in order to better
understand structure−activity relationship (SAR) of the right-
hand side chain, analogues featuring a terminal carboxylic acid,
trifluoromethoxy group, carbamate function, or six-membered
ring were designed. The syntheses of the cyclopropane
analogues 7, 10, 11, 14, 17a−c, 19a−b, and 21 are outlined
in Scheme 1. The optically pure alcohol 5 was acylated with
isobutyric anhydride, and the benzyl group was removed by
hydrogenolysis, followed by installation of the azetidine moiety
by a modified Mitsunobu reaction to obtain the intermediate 6.
Successive removal of the isobutyryl group and the Boc group
from 6 gave the desired product 7. For compound 10 with a
longer side chain, alcohol 5 was subjected to standard Swern
oxidation and Wittig reaction to furnish the α,β-unsaturated
ester 8. After removal of the benzyl group and saturation of the
double bond by catalytic hydrogenation in the same step, the
azetidine moiety was installed to give the ester 9. Reduction of
the ester group in the intermediate 9 and subsequent removal
of the Boc group gave compound 10. Hydrolysis of the ester 9
and then removal of the Boc group furnished the carboxylic
acid compound 11. For the terminal trifluoromethoxy
compound 14, the starting alcohol 12 was converted to
dithiocarbonate, followed by reaction with 70% HF/pyridine to
give hydroxypyridine 13 after removal of the benzyl group.19
Installation of the azetidine moiety and subsequent removal of
Boc group gave the desired product 14. The carbamate
analogues 19a and 19b were prepared from the previously
reported alcohol 15,15 which was transformed to the
corresponding iodide, followed by nucleophilic substitution
with sodium azide to give the intermediate 18. Reduction of the
azide group in compound 18 and subsequent reaction with
various chloroformates afforded the desired products after
removal of the Boc protecting group. Similarly, the iodide 16
was substituted by morpholine, piperidine, or piperazine and
the Boc group then removed to give 17a, 17b, and 17c,
respectively. Compound 21, the diastereoisomer of 17b, was
synthesized from alcohol 20 by the same sequence of steps. All
target compounds were isolated as their trifluoroacetate salts.
On the other hand, pyrrolidine, a higher homologue of
azetidine and a common heterocyclic building block in
Figure 1. Selected azetidine-containing compounds and nicotinic
ligands.
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medicinal chemistry, was chosen to replace the azetidine ring
and thus furnish a variety of pyrrolidine-containing derivatives.
The target molecules 23−31 were prepared through a
previously reported route employing the hydroxypyridine
intermediate 22 as the starting material (Scheme 2).15
Coupling of 22 with various alcohols to afford the
corresponding ethers was brought about using the Mitsunobu
reaction. Removal of the Boc group from the coupling
intermediates or reduction of the Boc or acetyl group to the
corresponding methyl or ethyl groups, respectively, gave the
desired products as their trifluoroacetate salts. Compound 33,
the diastereoisomer of 26, was synthesized from alcohol 32 by
the same sequence of steps.
■ RESULTS AND DISCUSSION
In Vitro Characterization: Radioligand Binding Stud-
ies. All of the synthesized compounds were first assayed for
[3H]epibatidine binding competition at seven, heterologously
expressed, rat nAChR subtypes. As shown in Table 1, these
compounds generally demonstrated favorable subtype selectiv-
ity for β2*-nAChRs (α2β2-, α3β2-, α4β2-, and α4β2*-
nAChRs) over β4*-nAChRs (α2β4-, α3β4-, and α4β4-
nAChRs) compared to nicotine. Compound 7 exhibited
subnanomolar binding affinity at both α4β2- and α4β2*-
nAChRs, while the Ki values were slightly higher for compound
3. In contrast, the activity for α4β2- or α4β2*-nAChRs was
retained when extending the side chain in compound 3 by one
more carbon atom (compound 10). In view of the existing
pharmacological data for the cyclopropane ligands15 combined
Scheme 1a
aReagents and conditions: (a) isobutyric anhydride, cat. 4-(dimethylamino)pyridine (DMAP), Et3N, CH2Cl2, rt; (b) 10% Pd/C, H2, EtOAc/MeOH,
rt; (c) 1-(tert-butoxycarbonyl)-(2S)-azetidinylmethanol, azodicarbonyldipiperidide (ADDP), P(n-Bu)3, PhMe, 0 °C to rt; (d) NaOMe, MeOH, 40
°C; (e) CF3COOH, CH2Cl2, rt; (f) (i) (COCl)2, DMSO, Et3N, CH2Cl2, −78 °C, (ii) Ph3PCHCO2CH3, THF, 0 °C to rt; (g) LiAlH4, THF, rt;
(h) 2N NaOH, MeOH/THF (1:1), rt; (i) (i) NaH, CS2, DMF, 0 °C to rt, (ii) MeI, rt; (j) 70% HF/pyridine, 1,3-dibromo-5,5-dimethylhydantoin
(DBH), CH2Cl2, −78 °C; (k) I2, PPh3, imidazole, 0 °C to rt; (l) morpholine, piperidine, or piperazine, CH3CN; (m) NaN3, DMF, 60 °C; (n) 10%
Pd/C, H2, ethanol, rt; (o) ethyl or isopropyl chloroformate, Et3N, 0 °C to rt.
Scheme 2a
aReagents and conditions: (a) azodicarbonyldipiperidide (ADDP),
P(n-Bu)3, alcohol, PhMe, 0 °C to rt; (b) CF3COOH, CH2Cl2, rt; (c)
LiAlH4, THF, reflux.
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with the knowledge obtained from the isoxazolylpyridine ether
analogues,18 a two-carbon alkyl linker between the chiral
cyclopropane and the terminal functional groups was optimal
for biological activity. In reference to the terminal hydroxyl
group, an at least 2-fold decline in binding affinities at β2*-
nAChRs was observed when converting the hydroxyl group in
compound 3 to a carboxylic acid (compound 11). The O-
methylation of compound 3 did not alter binding affinities and
selectivity for β2*-nAChRs. Moreover, this group would
preclude the possible metabolic liability of the hydroxyl
group, which can undergo oxidation and/or bioconjugation
reactions.20 The replacement of the methoxy group in
compound 4 with a more lipophilic and electron-withdrawing
trifluoromethoxy moiety (compound 14) caused a 7-fold
decrease in binding affinity for α4β2- or α4β2*-nAChRs and
significantly decreased the subtype selectivity for β2*- over
β4*-nAChRs. As previously reported, derivation of the
hydroxyl group in compound 3 to a variety of carbamate
groups in general maintained the high binding affinities at β2*-
nAChRs. The reversed carbamate derivatives 19a and 19b also
exhibited subnanomolar to low nanomolar binding affinities at
β2*-nAChRs, and binding affinities decreased as the size of
substituents at the carbamate oxygen increased. Introduction of
a saturated six-membered heterocycle at the end of the side
chain to replace the hydroxyl group (compounds 17a, 17b, and
17c) resulted in at least 2-fold less potency at β2*-nAChRs,
while a more polar heterocyclic ring was preferred in this
position (potency at α4β2-nAChRs: piperazine > morpholine >
piperidine). In addition, compound 21, bearing a (1R,2S)-
configured cyclopropane ring, was found to be about 10-fold
less active than its diastereoisomer 17b at both α4β2- and
α4β2*-nAChRs. Collectively, as shown in Table 1, these
compounds bearing a varied cyclopropane-containing side
chain generally were very potent at both α4β2- and α4β2*-
nAChRs, suggesting that variations in the terminal substituents
on the right-hand side chain do not significantly affect their
binding affinities, which is consistent with the previous
finding21 that the cyclopropane-containing side chain points
Table 1. Affinities of Compounds 7, 10, 11, 14, 17a−c, 19a−b, and 21 for Rat nAChR Subtypes Defined by Competition for
[3H]Epibatidine Binding
Ki (nM)
a
compd α2β2 α2β4 α3β2 α3β4 α4β2 α4β2*b α4β4
7 0.2 233.4 2.8 ± 0.5 6119 0.2 0.7 ± 0.1 78.1 ± 11.9
10 0.1 211.8 3.8 ± 0.6 7514 0.1 0.4 ± 0.1 88.1 ± 10.4
11 0.5 ± 0.1 318 10.2 ± 1.9 4290 0.2 1.6 ± 0.3 75.7 ± 16
14 1.1 ± 0.1 20.2 ± 4.1 17 ± 3.3 612.7 0.8 ± 0.1 3.5 ± 0.6 4.2 ± 0.3
17a 15.3 ± 1.1 NA 224 NA 11.3 ± 0.9 9.8 ± 2.1 NA
17b 14.9 ± 3.5 >104 403 NA 4.6 ± 0.4 10.4 ± 1.4 2930
17c 65.3 ± 14.4 NA 6.5 ± 1.9 NA 2.1 ± 0.3 1.7 ± 0.5 6237
19a 0.5 ± 0.1 203 8.9 ± 2.3 8830 0.4 ± 0.1 1.0 ± 0.1 125
19b 0.6 ± 0.1 453 11.1 ± 3.7 NA 0.5 ± 0.1 1.4 ± 0.2 158
21 89.7 ± 16 7850 1190 NA 56.1 ± 7.8 91.5 ± 14.3 2700
3c 0.1 249 3.0 6520 0.1 0.5 82.6
4c 0.1 236 2.4 NA 0.1 0.3 50.2
nicotined 5.5 70 29 260 4.9 9.8 23
saz-Ae 0.087 210 0.38 1900 0.062 0.17 52
aSee Experimental Section. SEM values are not provided for Ki values >100 nM.
bα4β2*, prepared from rat forebrain. cKi values for compounds 3
and 4 are obtained from ref 15. dKi values for nicotine are taken from the PDSP Assay Protocol Book (http://pdsp.med.unc.edu/).
eKi values for
sazetidine-A were obtained from the literature.22 NA: not active, defined as <50% binding in the primary assay at 10 μM.
Table 2. Affinities of Compounds 23−31 and 33 for Rat nAChR Subtypes Defined by Competition for [3H]Epibatidine Binding
Ki (nM)
a
compd α2β2 α2β4 α3β2 α3β4 α4β2 α4β2*b α4β4
23 NA NA NA NA 2176 NA NA
24 0.5 ± 0.1 612 17.3 ± 5.3 NA 0.4 ± 0.1 1.1 ± 0.2 161
25 18.1 ± 2.3 >104 2534 NA 38.8 ± 7 221 >104
26 0.2 129.5 21 ± 5.7 NA 0.3 0.5 ± 0.1 584.8
27 167.9 NA NA NA 49.5 ± 8.9 173.7 NA
28 43.8 ± 10.7 NA 2094 NA 28.5 ± 5.6 193.8 NA
29 12.9 ± 1.7 9959 472.5 NA 21.7 ± 6.6 86.6 ± 15.3 9475
30 0.04 50.8 ± 10.5 0.8 ± 0.2 2074 0.05 0.2 30 ± 4.3
31 6.1 ± 0.6 NA 191.5 NA 90.9 ± 27 40.7 ± 5.3 NA
33 3.5 ± 0.5 546.6 137.3 NA 3.3 ± 1 15.7 ± 2.8 234.1
4c 0.1 236 2.4 NA 0.1 0.3 50.2
nicotined 5.5 70 29 260 4.9 9.8 23
saz-Ae 0.087 210 0.38 1900 0.062 0.17 52
aSee Experimental Section. SEM values are not provided for Ki values >100 nM.
bα4β2*, prepared from rat forebrain. cKi values for compound 4 are
obtained from ref 15. dKi values for nicotine are taken from the PDSP Assay Protocol Book (http://pdsp.med.unc.edu/).
eKi values for sazetidine-A
were obtained from the literature.22 NA: not active, defined as <50% binding in the primary assay at 10 μM.
Journal of Medicinal Chemistry Article
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outward from the binding pocket without engaging in any
significant polar interactions based on the analysis of the
cocrystal structure of the acetylcholine binding protein from
Capitella teleta in complex with compound 3.
Next, we fixed the structure of the right-hand side chain and
explored a series of functional groups to replace the somewhat
labile azetidine unit. As shown in Table 2, replacement of the
azetidine ring as in compound 4 with an aliphatic amine
(compound 23) resulted in the complete loss of activity at all of
the nAChR subtypes tested with the exception of weak binding
affinity at α4β2-nAChRs (2.2 μM), suggesting that the
conformationally restricted azetidine ring plays an important
role in maintaining high binding affinity for the nAChRs. As the
smallest saturated azaheterocycle aziridine is highly reactive and
thus an unsuitable replacement for the azetidine, we thus chose
to examine the higher homologue of azetidine and thus
prepared the pyrrolidine analogue 24. This compound
exhibited subnanomolar to low nanomolar binding affinity at
the α4β2- and α4β2*-nAChRs and good selectivity for β2*-
nAChRs, similar to the parent compound 4. Further ring
expansion of the pyrrolidine ring to a piperidine ring
(compound 25) caused more than a 150-fold drop in binding
affinities at β2*-nAChRs. The presence of an N-methyl group,
as in compound 26, increased binding at the α4β2- or α4β2*-
nAChRs relative to compound 24, however, an N-ethyl group
(compound 27) remarkably reduced binding affinity for all
seven nAChRs. The fusion of a cyclopropane ring to the
pyrrolidine ring (compound 28) also caused a sharp decrease in
binding potency toward all nAChR subtypes tested, indicating
that the space in the cation-binding pocket accommodating the
pyrrolidine ring is limited. With respect to stereoselectivity,
compound 26 was at least 70-fold or 10-fold more potent at the
α4β2- and α4β2*-nAChRs than its diastereoisomers 29 and 33,
respectively, indicating that an (S)-configuration of the N-
methyl-pyrrolidine and a cyclopropane ring with the (1S,2R)-
configuration were preferred. Shifting the nitrogen atom in the
pyrrolidine ring of compound 24 to the less-substituted α-
methylene position gave compound 30, having the highest
binding affinity at β2*-nAChRs in this series while exhibiting
weak activity at α3β4-nAChRs (2 μM). Modification of
compound 30 by deletion of the methylene group connecting
the pyrrolidine ring with the 3-pyridyl ether framework led to
compound 31, which showed a significant decrease in binding
potency at all nAChR subtypes tested. In spite of the fact that
some of the compounds listed in Table 2 had only modest
activity at α4β2-nAChRs, most of them generally presented
good subtype-selectivity for β2*-nAChRs over β4*-nAChRs
compared to nicotine. On the basis of previous findings that
α4β2-nAChR ligands featuring distinct chemical scaffolds can
engage in similar receptor interactions,21 we anticipate that the
cyclopropane-containing side chain could be appended to other
α4β2-nAChR ligands with diverse scaffolds to improve their
subtype selectivity.
In Vitro Functional Characterization. In functional
studies, the most promising compounds, 24, 26, and 30, were
tested using 86Rb+ ion flux assays in SH-EP1-hα4β2 (expressing
human α4β2-nAChRs), SH-EP1-h(α6/3)β2β3 (expressing
human (α6/3)β2β3-nAChRs; referred to as α6*-nAChRs),
SH-SY5Y (α3β4*-nAChRs), or TE671/RD (α1β1γδ-nAChRs)
cells. Abilities of ligands to stimulate ion flux were characterized
as EC50 values with efficacies normalized to that of
carbamylcholine. Abilities of chronically administered ligands
to inhibit ion flux were characterized as inactivation IC50 values
following the 10 min preincubation used to characterize
receptor stimulation.
These pyrrolidine analogues were found to be highly potent,
partial agonists at the mixture of high sensitivity (HS) and low
sensitivity (LS) α4β2-nAChRs and to have weak if any agonist
activity at α3β4*- or α1β1γδ-nAChRs. Their EC50 values were
comparable to that found for parent compound 4, with the
exception of compound 30, possessing an EC50 value in the
single-digit nanomolar range, and the trend was consistent with
results observed in the binding studies (Table 3 and Supporting
Information Figure S2). Response magnitude (efficacy) was
29−92% relative to a maximally efficacious concentration of the
full agonist, carbamylcholine, for action at HS α4β2-nAChRs.
At LS α4β2-nAChRs, these ligands had no measurable efficacy
as agonists. Their inactivation of nAChR function was most
potent for α4β2-nAChRs and weak or absent for actions at
α3β4*- or α1β1γδ-nAChRs. IC50 values for compounds 26 and
30 were 4-fold higher or similar to that of compound 4,
respectively, while compound 24 was 20-fold less potent. The
absence or weakness of agonist or antagonist activity at
ganglionic α3β4*- or muscle-type α1β1γδ-nAChRs indicates
that the occurrence of peripheral side effects is unlikely. All of
the pyrrolidine analogues had agonist activity at α6*-nAChRs
with EC50 values in the range of 9.0−51.5 nM. Their agonism
efficacies were relatively low, ranging from 4.9 to 12% of the
maximum response to carbamylcholine. This low-efficacy
agonism correlates with inactivation efficacies that are much
higher than that seen for nicotine (Table 3). Inactivation IC50
values of these ligands were lower than 24 nM, with the
exception of compound 24, having an IC50 value greater than
220 nM.
In Vivo Behavioral Pharmacology. To determine
whether the excellent potency of the pyrrolidine analogues at
α4β2-nAChRs would translate into antidepressant-like efficacy
in a behavioral model, compounds 24, 26, and 30 were
Table 3. Potencies and Efficacies of Ligand Agonism and Inactivation of Human α4β2- and α6*- nAChRsa
agonism inactivation
α4β2 α6* α4β2 α6*
compd EC50 (nM) efficacy at HS (%)
b,c EC50 (nM) efficacy (%) IC50 (nM) efficacy (%)
b IC50 (nM) efficacy (%)
24 23 29 ± 2.5 51.5 4.9 ± 0.6 108 84 ± 4.6 223 79 ± 5.6
26 14.4 49 ± 5.2 9.0 6.5 ± 0.4 20 88 ± 2.7 23.9 87 ± 1.5
30 6.2 92 ± 1.5 23.5 12 ± 0.6 5.5 70 ± 3.3 8.3 76 ± 0.7
4 17.5 60 ± 5.9 7.4 6.2 ± 0.3 5.6 71 ± 5.5 9.7 80 ± 3.5
nicotine 290 125 ± 10 127 56 ± 0.8 430 92 ± 2.1 84.8 26 ± 1.0
aSee Experimental Section. bEfficacies were measured in a mixture of HS and LS α4β2-nAChRs. cEfficacy values for actions at HS α4β2-nAChR
were extrapolated from results obtained using sazetidine-A as a full agonist at HS α4β2-nAChR (see Supporting Information for details).
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investigated in the mouse forced swim test,23 an assay in which
mice are placed into a beaker of water and the time the mouse
spends passively floating in the water (immobility) is recorded.
Most traditional antidepressants decrease the amount of time
mice spend immobile. Mice were administered nicotinic ligands
or the selective serotonin reuptake inhibitor, sertraline, as a
positive control (20 mg/kg). Compound 24 showed no
significant effects in the forced swim test when administered
intraperitoneally at a dose of 1, 3, or 10 mg/kg (Supporting
Information Figure S3), likely due to its lower inhibitory
potency at both α4β2- and α6*- nAChRs relative to the parent
compound 4. On the other hand, the N-methylpyrrolidine
analogue 26 demonstrated an antidepressant-like effect when
administered intraperitoneally or orally, with a significant
reduction in immobility at the minimal dose of 1 mg/kg
(Figure 2). It appears that the N-methyl group in compound 26
is crucial to maintaining in vivo activity. Intraperitoneal
administration of the most potent compound 30 in vitro,
however, produced abnormal behavioral effects, such as
sedation and tremor at 5 mg/kg, and resulted in death of the
mice during the pretreatment or trial at 10 mg/kg.
Preliminary ADMET Study. Encouraged by the favorable
biological data, we submitted compound 26 for preliminary
ADMET tests (Table 4).24 When incubated with human or
mouse (CD-1) liver microsomes, at least 90% of compound 26
remained unchanged after 1 h incubation at 0.1 μM. Incubation
with human hepatocytes resulted in more than 85% of
compound 26, remaining unchanged after 2 h incubation at 1
μM. In the presence of compound 26 at a concentration of 10
μM, none of the CYP isoforms tested (CYP1A, CYP2C9,
CYP2C19, and CYP3A) showed more than 30% inhibition,
suggesting minimal adverse drug−drug interactions, with the
exception of 44% inhibition of the CYP2D6 isoform. Plasma
protein binding (PPB) assays were conducted with both human
and mouse (CD-1) plasma at a concentration of 10 μM of
compound 26. In human plasma, 31% binding was observed,
while in mouse plasma the bound fraction was 11%. In the
bidirectional Caco-2 cell permeability assay, compound 26 was
found to exhibit high permeability and had an acceptable efflux
ratio of 0.2. In addition, the efflux ratio increased to 0.7 when
compound 26 was incubated in the present of verapamil, a P-
glycoprotein (P-gp) inhibitor, indicating that the test
compound is not a P-gp substrate. The bacteria reversion
mutation assay (Ames Test) was used to evaluate the
mutagenic potential of compound 26. At all concentrations
tested (5, 10, 50, and 100 μM), no positive significance was
observed for compound 26 in all tested strains (TA98, TA100,
TA1535, and TA1537) in the presence and absence of a liver
metabolic activation system (S9 fraction), with the exception of
higher concentrations (50 and 100 μM), at which compound
26 exhibited positive significance when tested using strain
TA1537 in the presence of the S9 fraction. However, when the
Ames genotoxicity testing was repeated using the tartrate salt of
compound 26 and the TA1537 tester strain with or without
metabolic activation, the compound was found not to be
mutagenic at all concentrations tested (up to 3 × 105 μM).
Cardiotoxicity associated with the inhibition of human hERG
was also evaluated at three test concentrations (0.1, 1, and 10
μM). Compound 26 led to 4%, 7%, and 23% inhibition of tail
current, respectively. Moreover, compound 26 was found to be
quite chemically stable, as it could be stored at room
temperature for several months showing little or no sign of
decomposition.
■ CONCLUSION
In this report, we disclose the synthesis, pharmacological
characterization, and structure−activity relationships of a series
of cyclopropane-containing nAChR ligands. Modifications to
both the azetidine ring present in the lead compound 3 and its
right-hand side chain have been explored to improve
compound druggability. We successfully identified potent and
highly selective α4β2-nAChR partial agonists 24, 26, and 30
Figure 2. Mouse forced swim data for compound 26. The selective serotonin reuptake inhibitor, sertraline, produced the expected decrease in
immobility. ANOVAs: F (4,43) = 34.20, p < 0.001 (left); F (4,44) = 20.75, p < 0.001 (right). *Fisher’s PLSD posthoc test: ps < 0.05 vs vehicle. n =
910/group.
Table 4. ADMET Properties of Compound 26
assay compound 26
liver microsomes (human or mouse, 0.1 μM) (%) 103.3 or 90.1
cryopreserved hepatocytes (human, 1 μM) (%) 85.7
CYP inhibition (10 μM) (%)
CYP1A 17
CYP2C9 30
CYP2C19 21
CYP2D6 44
CYP3A 10
hERG inbihition (0.1, 1, 10 μM) (%) 4, 7, 23
plasma protein binding (human or mouse, 10 μM) (%) 31 or 11
A−B permeability (Caco-2, pH 7.4/7.4) (cm/s) 90.9 × 10−6
A−B permeability (Caco-2, pH 7.4/7.4 + verapamil) (cm/s) 79.2 × 10−6
B−A permeability (Caco-2, pH 7.4/7.4) (cm/s) 18.4 × 10−6
B−A permeability (Caco-2, pH 7.4/7.4 + verapamil) (cm/s) 55.2 × 10−6
Ames test (strain TA98, TA100, TA1535, TA1537, with/
without S9)
negative
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that exhibited comparable or improved pharmacological
parameters in comparison to compound 3 in [3H]epibatidine
binding studies as well as functional assays based on 86Rb+ ion
flux measurements. In addition, minor changes such as
incorporation of a methyl group (24 vs 26) or alteration of
the position of the nitrogen atom as in the pyrrolidines 24 vs 30
may significantly affect the in vivo activity of these nicotinic
ligands. Compound 26 demonstrated favorable antidepressant-
like effects in the mouse forced swim test while possessing a
favorable ADMET profile and chemical stability. Together,
these findings support compound 26 as a promising lead
candidate that deserves further evaluation in the design of
antidepressants possessing a unique mechanism of action.
■ EXPERIMENTAL SECTION
General. All chemicals were purchased from Sigma-Aldrich or
Chem-Impex, and solvents were used as obtained from Fisher
Scientific or Sigma-Aldrich without further purification. Anhydrous
THF and CH2Cl2 were obtained by distillation over sodium wire or
CaH2, respectively. All nonaqueous reactions were run under an argon
atmosphere with exclusion of moisture from reagents, and all reaction
vessels were oven-dried. The progress of the reactions was monitored
by TLC on SiO2. Spots were visualized by their quenching of the
fluorescence of an indicator admixed to the SiO2 layer or by dipping
into I2/SiO2 mixture. Products were purified by column chromatog-
raphy on 230−400 mesh SiO2. Proton and carbon NMR spectra were
recorded at spectrometer frequencies of 400 and 100 MHz,
respectively. NMR chemical shifts were reported in δ (ppm) using
the δ 7.26 signal of CHCl3 (
1H NMR), the δ 4.80 signal of HDO (1H
NMR), and the δ 77.23 signal of CDCl3 (
13C NMR) as internal
standards. 13C NMR spectra in D2O were not adjusted. Optical
rotation was detected on an Autopol IV automatic polarimeter. Mass
spectra were measured in the ESI mode at an ionization potential of 70
eV with an LC-MS MSD (Hewlett-Packard). The final compounds
were purified by preparative HPLC, which was carried out on an ACE
5 AQ column (150 mm × 20 mm), with detection at 254 and 280 nm
on a Shimadzu SPD-10A VP detector; flow rate = 17.0 mL/min;
gradient of 0−50% methanol in water (both containing 0.05 vol% of
CF3COOH) in 30 min. Purities of final compounds (>98%) were
established by both elemental analysis and by analytical HPLC, which
was carried out on an Agilent 1100 HPLC system with a Synergi 4 μm
Hydro-RP 80A column, with detection at 254 or 280 nm on a variable
wavelength detector G1314A; flow rate = 1.4 mL/min; gradient of 0−
100% methanol in water (both containing 0.05 vol% of CF3COOH) in
18 min. See Supporting Information for detailed experimental
procedures and NMR spectral data (1H and 13C) of all intermediates.
3-[(2(S)-Azetidinyl)methoxy]-5-[(1S,2S)-2-(hydroxymethyl)-
cyclopropyl]pyridine Trifluoroacetate (7). 1H NMR (D2O): δ
8.36 (s, 1H), 8.28 (s, 1H), 7.91 (s, 1H), 4.98 (m, 1H), 4.53 (d, J = 3.6
Hz, 2H), 4.12 (m, 2H), 3.69 (m, 1H), 3.54 (m, 1H), 2.70 (q, J = 8.4
Hz, 2H), 2.12 (m, 1H), 1.64 (m, 1H), 1.22 (t, J = 7.2 Hz, 2H). 13C
NMR (D2O): δ 162.3 (TFA), 155.9, 145.2, 132.2, 128.3, 125.7, 115.8
(TFA), 67.2, 64.1, 58.2, 43.3, 25.4, 19.8, 18.1, 14.1. [α]D
20 = +27.7 (c
0.48, MeOH). Anal. Calcd for C13H18N2O2·2.15CF3COOH·0.85H2O:
C, 42.0; H, 4.45; F, 24.77; N, 5.66. Found: C, 41.89; H, 4.18; F, 24.51;
N, 5.55. HPLC purity = 99.1%; tR = 6.1 min.
3-[(2(S)-Azetidinyl)methoxy]-5-[(1S,2S)-2-(3-hydroxypropyl)-
cyclopropyl]pyridine Trifluoroacetate (10). 1H NMR (D2O): δ
8.32 (s, 1H), 8.22 (s, 1H), 7.84 (s, 1H), 4.98 (m, 1H), 4.53 (d, J = 4.0
Hz, 2H), 4.11 (m, 2H), 3.63 (t, J = 6.6 Hz, 2H), 2.70 (q, J = 8.4 Hz,
2H), 1.93 (m, 1H), 1.69 (m, 2H), 1.56−1.44 (m, 2H), 1.31 (m, 1H),
1.14 (m, 2H). 13C NMR (D2O): δ 162.4 (TFA), 155.8, 146.6, 131.9,
127.8, 125.2, 115.8 (TFA), 67.1, 60.9, 58.2, 43.3, 30.4, 29.0, 25.0, 19.8,
19.7, 16.9. [α]D
20 = +10.0 (c 1.1, MeOH). Anal. Calcd for
C15H22N2O2·2.55CF3COOH·0.75H2O: C, 42.61; H, 4.63; F, 25.65,
N, 4.94. Found: C, 42.70; H, 4.51; F, 25.55; N, 4.97. HPLC purity =
99.2%; tR = 6.1 min.
3-[(1S,2S)-2-[5-[((S)-Azetidin-2-yl)methoxy]pyridin-3-yl]-
cyclopropyl]propanoic Acid Trifluoroacetate (11). 1H NMR
(D2O): δ 8.34 (s, 1H), 8.22 (s, 1H), 7.85 (s, 1H), 4.98 (m, 1H), 4.52
(d, J = 4.0 Hz, 2H), 4.12 (m, 2H), 2.70 (q, J = 8.4 Hz, 2H), 2.53 (m,
2H), 1.99 (m, 1H), 1.84 (m, 1H), 1.68 (1H), 1.33 (m, 1H), 1.17 (m,
2H). 13C NMR (D2O): δ 178.1, 162.4 (TFA), 155.8, 146.1, 132.0,
127.9, 125.4, 115.9 (TFA), 67.1, 58.2, 43.3, 33.1, 28.2, 24.2, 19.8, 19.7,
16.3. [α]D
20 = +32.5 (c, 0.36 MeOH). Anal. Calcd for
C15H20N2O3·2.15CF3COOH·0.9H2O: C, 43.11; H, 4.49; F, 22.79,
N, 5.21. Found: C, 42.96; H, 4.24; F, 22.53; N, 5.16. HPLC purity =
99.8%; tR = 7.0 min.
3 - [ ( 2 ( S ) - A z e t i d i n y l )me t h o x y ] - 5 - [ ( 1 S , 2R ) - 2 - ( 2 -
trifluoromethoxyethyl)cyclopropyl]pyridine Trifluoroacetate
(14). 1H NMR (D2O): δ 8.33 (s, 1H), 8.22 (s, 1H), 7.85 (s, 1H),
4.96 (m, 1H), 4.51 (d, J = 3.6 Hz, 2H), 4.18−4.03 (m, 4H), 2.68 (q, J
= 8.4 Hz, 2H), 2.02 (m, 1H), 1.92 (m, 1H), 1.73 (m, 1H), 1.37 (m,
1H), 1.19 (m, 2H). 13C NMR (D2O): δ 162.5 (TFA), 156.2, 146.3,
132.4, 128.4, 125.9, 121.5 (q, JC−F = 251.1 Hz), 116.2 (TFA), 67.7,
67.6, 58.6, 43.6, 32.1, 21.8, 20.2, 19.7, 16.1. 19F NMR (D2O): δ −60.2,
−75.6. [α]D20 = +28.6 (c 0.14, MeOH). Anal. Calcd for
C15H19F3N2O2·2.4CF3COOH·0.5H2O: C, 39.7; H, 3.77; F, 32.35;
N, 4.68. Found: C, 39.47; H, 3.52; F, 32.14; N, 4.49. HPLC purity =
99.8%; tR = 9.7 min.
3-[(2(S)-Azetidinyl)methoxy]-5-[(1S,2R)-2-(2-(piperidin-1-yl)-
ethyl)cyclopropyl]pyridine Trifluoroacetate (17a). 1H NMR
(D2O): δ 8.37 (s, 1H), 8.25 (s, 1H), 7.87 (s, 1H), 4.99 (m, 1H),
4.54 (s, 2H), 4.18−4.08 (m, 2H), 3.52 (d, J = 6.0 Hz, 2H), 3.23 (t, J =
8.0 Hz, 2H), 2.93 (t, J = 8.0 Hz, 2H), 2.67 (dd, J = 12.0, 4.0 Hz, 2H),
2.01 (m, 1H), 1.97−1.70 (m, 7H), 1.49−1.46 (m, 1H), 1.35−1.33 (m,
1H), 1.24−1.19 (m, 2H). 13C NMR (D2O): δ 162.7 (TFA), 156.2,
145.6, 132.4, 128.5, 126.0, 116.3 (TFA), 67.5, 58.6, 53.1, 27.5, 22.7,
21.5, 21.0, 20.2, 19.8, 16.3. [α]D
20 = +43.6 (c = 3.4, MeOH). Anal.
Calcd for C19H29N3O·3.1CF3COOH·0.45H2O: C, 44.71; H, 4.91; F,
26.1; N, 6.21. Found: C, 44.83; H, 4.77; F, 25.97; N, 6.14. HPLC
purity = 99.8%; tR = 4.1 min.
3-[(2(S)-Azetidinyl)methoxy]-5-[(1S,2R)-2-(2-(morpholin-4-
yl)ethyl)cyclopropyl]pyridine Trifluoroacetate (17b). 1H NMR
(D2O) δ 8.33 (s, 1H), 8.21 (s, 1H), 7.82 (s, 1H), 4.96−4.94 (m, 1H),
4.50 (d, J = 4.0 Hz, 2H), 4.14−4.05 (m, 4H), 3.78 (t, J = 12.4 Hz, 2H),
3.50 (d, J = 12.8 Hz, 2H), 3.29 (t, J = 8.0 Hz, 2H), 3.16 (dt, J = 12.4,
3.2 Hz, 2H), 2.67 (q, J = 8.8 Hz, 2H), 2.05−2.03 (m, 1H), 1.91−1.85
(m, 2H), 1.30 (m, 1H), 1.21−1.15 (m, 2H). 13C NMR (D2O): δ 162.2
(TFA), 155.8, 145.1, 132.0, 128.1, 125.7, 115.9 (TFA), 67.1, 63.3,
58.2, 55.9, 51.2, 43.2, 26.7, 20.8, 19.8, 19.4, 15.9. [α]D
20 = +43.5 (c =
0.8, MeOH). Anal. Calcd for C18H27N3O2·3.4CF3COOH·0.4H2O: C,
41.82; H, 4.41; F, 27.2; N, 5.9. Found: C, 41.91; H, 4.31; F, 27.09; N,
5.96. HPLC purity = 99.6%; tR = 3.9 min.
3-[(2(S)-Azetidinyl)methoxy]-5-[(1S,2R)-2-(2-(piperazin-1-yl)-
ethyl)cyclopropyl]pyridine Trifluoroacetate (17c). 1H NMR
(D2O): δ 8.37 (s, 1H), 8.25 (s, 1H), 7.85 (s, 1H), 4.98 (m, 1H),
4.53 (d, J = 4.0 Hz, 2H), 4.17−4.05 (m, 2H), 3.65 (br s, 8H), 3.44 (t, J
= 8.4 Hz, 2H), 2.71 (q, J = 8.4 Hz, 2H), 2.09 (m, 1H), 2.02−1.87 (m,
2H), 1.36 (m, 1H), 1.26−1.18 (m, 2H). 13C NMR (D2O): 162.3
(TFA), 155.9, 145.0, 132.1, 128.2, 125.7, 115.9 (TFA), 67.2, 58.2,
55.9, 48.0, 43.3, 40.2, 26.9, 20.6, 19.8, 19.4, 15.9. [α]D
20 = +36.4 (c
1.52, MeOH). Anal. Calcd for C18H28N4O·4.05CF3COOH·0.45H2O:
C, 39.86; H, 4.22; F, 29.36; N, 7.12. Found: C, 39.97; H, 4.23; F,
29.26; N, 7.03. HPLC purity = 99.7%; tR = 4.8 min.
Ethyl [2-[(1R,2S)-2-[5-[((S)-Azetidin-2-yl)methoxy]pyridin-3-
yl]cyclopropyl]ethyl]carbamate Trifluoroacetate (19a). 1H
NMR (D2O): δ 8.32 (s, 1H), 8.21 (s, 1H), 7.82 (s, 1H), 4.97 (m,
1H), 4.51 (d, J = 4.4 Hz, 2H), 4.12 (m, 2H), 3.94 (m, 2H), 3.23 (m,
2H), 2.68 (q, J = 8.4 Hz, 2H), 1.94 (m, 1H), 1.70 (m, 1H), 1.50 (m,
1H), 1.27 (m, 1H), 1.15−1.10 (m, 5H). 13C NMR (D2O): δ 162.6
(TFA), 158.7, 156.2, 146.7, 132.2, 128.2, 125.6, 116.3 (TFA), 67.5,
61.5, 58.6, 43.6, 40.0, 33.1, 23.2, 20.2, 20.0, 16.5, 13.7. [α]D
20 = +35.0
(c 0.20, MeOH). Anal. Calcd for C17H25N3O3·2.6CF3COOH·
0.55H2O: C, 42.61; H, 4.62; F, 23.68, N, 6.71. Found: C, 42.75; H,
4.58; F, 23.55; N, 6.63. HPLC purity = 99.8%; tR = 6.8 min.
Isopropyl [2-[(1R,2S)-2-[5-[((S)-Azetidin-2-yl)methoxy]-
pyridin-3-yl]cyclopropyl]ethyl]carbamate Trifluoroacetate
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(19b). 1H NMR (D2O): δ 8.32 (s, 1H), 8.20 (s, 1H), 7.81 (s, 1H),
4.96 (m, 1H), 4.65 (m, 1H), 4.50 (d, J = 3.2 Hz, 2H), 4.10 (m, 2H),
3.22 (m, 2H), 2.67 (q, J = 8.4 Hz, 2H), 1.93 (m, 1H), 1.69 (m, 1H),
1.50 (m, 1H), 1.26 (m, 1H), 1.12 (m, 8H). 13C NMR (D2O): δ 162.5
(TFA), 158.3, 156.2, 146.7, 132.2, 128.2, 125.6, 116.2 (TFA), 69.3,
67.5, 58.6, 43.6, 39.9, 33.1, 23.1, 21.1, 20.2, 20.0, 16.6. [α]D
20 = +40.0
(c 0.24, MeOH). Anal. Calcd for C18H27N3O3·2.35CF3COOH·
0.2H2O: C, 45.07; H, 4.96; F, 22.14, N, 6.95. Found: C, 44.99; H,
4.87; F, 22.07; N, 6.95. HPLC purity = 99.7%; tR = 7.3 min.
3-[(2(S)-Azetidinyl)methoxy]-5-[(1R,2S)-2-(2-(morpholin-4-
yl)ethyl)cyclopropyl]pyridine Trifluoroacetate (21). 1H NMR
(D2O) δ 8.37 (s, 1H), 8.26 (s, 1H), 7.87 (s, 1H), 5.00−4.98 (m, 1H),
4.54 (d, 2H, J = 4.0 Hz), 4.17−4.08 (m, 4H), 3.82 (t, 2H, J = 12.4 Hz),
3.54 (d, 2H, J = 12.8 Hz), 3.34 (t, 2H, J = 8.0 Hz), 3.20 (dt, 2H, J =
12.4, 3.2 Hz), 2.71 (q, 2H, J = 8.8 Hz), 2.10−2.08 (m, 1H), 1.97−1.88
(m, 2H), 1.35 (m, 1H), 1.25−1.98 (m, 2H). 13C NMR (D2O): δ 162.2
(TFA), 155.9, 145.1, 132.1, 128.1, 125.7, 115.9 (TFA), 67.1, 63.3,
58.2, 55.9, 51.2, 43.2, 26.7, 20.8, 19.8, 19.4, 15.9. [α]D
20 = −46.4 (c
0.78, MeOH). Anal. Calcd for C18H27N3O2·3.4CF3COOH·0.05H2O:
C, 42.19; H, 4.35; F, 27.45; N, 5.95. Found: C, 42.22; H, 4.38; F,
27.38; N, 5.97. HPLC purity = 99.9%; tR = 3.9 min.
3 - [ 2 - ( I s op ropy l am ino ) e t hoxy ] - 5 - [ ( 1 S , 2R ) - 2 - ( 2 -
methoxyethyl)cyclopropyl]pyridine Trifluoroacetate (23). 1H
NMR (D2O): δ 8.14 (s, 1H), 8.07 (s, 1H), 7.66 (s, 1H), 4.35 (t, J =
4.0 Hz, 2H), 4.46−4.36 (m, 5H), 3.20 (s, 3H), 1.83 (s, 1H), 1.57 (s,
2H), 1.23 (d, J = 6.4 Hz, 6H), 1.16 (m, 1H), 1.02 (m, 2H). 13C NMR
(D2O): δ 162.4 (TFA), 156.1, 146.5, 132.2, 128.2, 125.6, 116.2 (TFA),
71.8, 64.9, 57.7, 51.1, 43.3, 32.6, 22.3, 19.8, 18.0, 16.6. [α]D
20 = +33.4
(c = 0.9, MeOH). Anal. Calcd for C16H26N2O2·2.15CF3COOH·
0.8H2O: C, 45.32; H, 5.57; F, 22.78; N, 5.21. Found: C, 45.06; H,
5.24; F, 22.63; N, 5.09. HPLC purity = 99.8%; tR = 9.3 min.
3 - [ ( 2 (S ) - Py r ro l i d i ny l )me thoxy ] - 5 - [ ( 1S , 2R ) - 2 - ( 2 -
methoxyethyl)cyclopropyl]pyridine Trifluoroacetate (24). 1H
NMR (D2O): δ 8.26 (s, 1H), 8.19 (s, 1H), 7.77 (s, 1H), 4.53 (dd, J =
10.4, 2.4 Hz, 1H), 4.33 (m, 1H), 4.11 (m, 1H), 3.56 (t, J = 6.4 Hz,
2H), 3.39 (t, J = 7.2 Hz, 2H), 3.32 (s, 3H), 2.27 (m, 1H), 2.12−2.06
(m, 2H), 1.94 (m, 2H), 1.68 (m, 2H), 1.28 (m, 1H), 1.12 (m, 2H).
13C NMR (D2O): δ 162.6 (TFA), 156.1, 146.5, 132.3, 128.2, 125.6,
116.2 (TFA), 71.8, 67.6, 58.3, 57.7, 45.9, 32.6, 25.7, 23.4, 22.3, 19.8,
16.6. [α]D
20 = +47.3 (c 0.28, MeOH). Anal. Calcd for
C16H24N2O2·2.05CF3COOH·0.05H2O: C, 47.24; H, 5.16; F, 22.86;
N, 5.48. Found: C, 47.30; H, 5.24; F, 22.75, N, 5.46. HPLC purity =
99.5%; tR = 7.6 min.
3-[(2(S)-Piperidinyl)methoxy]-5-[(1S,2R)-2-(2-methoxyethyl)-
cyclopropyl]pyridine Trifluoroacetate (25). 1H NMR (D2O): δ
8.22 (s, 1H), 8.16 (s, 1H), 7.74 (s, 1H), 4.39 (m, 1H), 4.24 (m, 1H),
3.61 (m, 1H), 3.54 (t, J = 6.4 Hz, 2H), 3.43 (m, 1H), 3.30 (s, 3H),
3.03 (m, 1H), 1.97−1.88 (m, 4H), 1.68−1.58 (m, 5H), 1.25 (m, 1H),
1.10 (m, 2H). 13C NMR (D2O): δ 162.2 (TFA), 155.7, 146.1, 131.9,
127.8, 125.2, 115.7 (TFA), 71.4, 68.7, 57.3, 54.9, 44.2, 32.2, 23.9, 21.9,
21.2, 20.6, 19.4, 16.2. [α]D
20 = +49.3 (c 0.53, MeOH). Anal. Calcd for
C17H26N2O2·2.6CF3COOH·1.05H2O: C, 44.02; H, 5.11; F, 24.46, N,
4.62. Found: C, 44.04; H, 4.89; F, 24.27; N, 4.78. HPLC purity =
98.7%; tR = 7.9 min.
3-[(1-Methyl-2(S)-pyrrolidinyl)methoxy]-5-[(1S,2R)-2-(2-
methoxyethyl)cyclopropyl]pyridine Trifluoroacetate (26). 1H
NMR (D2O): δ 8.30 (s, 1H), 8.23 (s, 1H), 7.81 (s, 1H), 4.61 (dd, J =
10.8, 2.8 Hz, 1H), 4.45 (m, 1H), 3.95 (m, 1H), 3.76 (m, 1H), 3.59 (t, J
= 6.4 Hz, 2H), 3.34 (s, 3H), 3.25 (m, 1H), 3.04 (s, 3H), 2.40 (m, 1H),
2.18 (m, 1H), 2.09 (m, 2H), 1.98 (m, 1H), 1.71 (m, 2H), 1.31 (m,
1H), 1.15 (m, 2H). 13C NMR (D2O): δ 162.0 (TFA), 155.6, 146.2,
132.0, 127.8, 125.2, 115.7 (TFA), 71.4, 66.9, 66.0, 57.3, 56.8, 40.2,
32.2, 25.4, 21.9, 21.7, 19.4, 16.2. [α]D
20 = +37.0 (c 0.27, MeOH). Anal.
Calcd for C17H26N2O2·2.4CF3COOH·0.4H2O: C, 45.83; H, 5.15; F,
23.94; N, 4.9. Found: C, 45.64; H, 4.91; F, 23.8, N, 4.9. HPLC purity
= 98.9%; tR = 7.8 min.
3-[(1-Ethyl-2(S)-pyrrolidinyl)methoxy]-5-[(1S,2R)-2-(2-
methoxyethyl)cyclopropyl]pyridine Trifluoroacetate (27). 1H
NMR (D2O): δ 8.30 (s, 1H), 8.23 (s, 1H), 7.80 (s, 1H), 4.57 (m, 1H),
4.44 (m, 1H), 4.05 (m, 1H), 3.73 (m, 1H), 3.61−3.54 (m, 3H), 3.35
(s, 3H), 3.24 (2H), 2.34 (m, 1H), 2.09−1.97 (m, 4H), 1.71 (m, 2H),
1.38−1.32 (m, 4H), 1.15 (m, 2H). 13C NMR (D2O): δ 161.9 (TFA),
155.6, 146.2, 132.1, 127.8, 125.2, 115.9 (TFA), 71.5, 66.5, 65.5, 57.3,
53.8, 50.1, 32.2, 25.5, 22.0, 21.9, 19.4, 16.2, 9.6. [α]D
20 = +39.8 (c 0.61,
MeOH). Anal. Calcd for C18H28N2O2·2.1CF3COOH·0.85H2O: C,
47.68; H, 5.73; F, 21.4, N, 5.01. Found: C, 47.4; H, 5.42; F, 21.32; N,
4.91. HPLC purity = 99.3%; tR = 8.0 min.
3-[((1S,2S,5R)-3-Azabicyclo[3.1.0]hexan-2-yl)methoxy]-5-
[(1S,2R)-2-(2-methoxyethyl)cyclopropyl]pyridine Trifluoroace-
tate (28). 1H NMR (D2O): δ 8.25 (s, 1H), 8.17 (s, 1H), 7.76 (s, 1H),
4.67 (d, J = 14.0 Hz, 1H), 4.35−4.27 (m, 2H), 3.55−3.45 (m, 4H),
3.30 (s, 3H), 1.94−1.88 (m, 3H), 1.66 (m, 2H), 1.26 (m, 1H), 1.10
(m, 2H), 0.84 (m, 1H), 0.59 (m, 1H). 13C NMR (D2O): δ 162.4
(TFA), 156.2, 146.5, 132.2, 128.2, 125.6, 117.6 (TFA), 71.8, 67.7,
59.3, 57.7, 47.6, 32.6, 22.3, 19.8, 16.6, 15.9, 14.1, 3.9. [α]D
20 = +34.3 (c
= 2.4, MeOH). Anal. Calcd for C17H24N2O2·2.15CF3COOH·
0.85H2O: C, 46.61; H, 5.11; F, 22.33; N, 5.1. Found: C, 46.62; H,
4.92; F, 22.14; N, 5.13. HPLC purity = 99.5%; tR = 12.7 min.
3-[(1-Methyl-2(R)-pyrrolidinyl)methoxy]-5-[(1S,2R)-2-(2-
methoxyethyl)cyclopropyl]pyridine Trifluoroacetate (29). 1H
NMR (D2O): δ 8.29 (s, 1H), 8.21 (s, 1H), 7.79 (s, 1H), 4.60 (dd, J =
10.8, 2.8 Hz, 1H), 4.43 (m, 1H), 3.94 (m, 1H), 3.74 (m, 1H), 3.57 (t, J
= 6.4 Hz, 2H), 3.32 (s, 3H), 3.24 (m, 1H), 3.02 (s, 3H), 2.39 (m, 1H),
2.19 (m, 1H), 2.07 (m, 2H), 1.96 (m, 1H), 1.69 (m, 2H), 1.29 (m,
1H), 1.13 (m, 2H). 13C NMR (D2O): δ 162.2 (TFA), 155.7, 146.2,
132.1, 127.9, 125.2, 115.8 (TFA), 71.4, 66.9, 66.0, 57.3, 56.8, 40.1,
32.2, 25.4, 22.0, 21.7, 19.4, 16.2. [α]D
20 = +39.5 (c 0.2, MeOH). Anal.
Calcd for C17H26N2O2·2.1CF3COOH·0.75H2O: C, 46.86; H, 5.49; F,
22.03; N, 5.16. Found: C, 46.96; H, 5.14; F, 21.7, N, 5.12. HPLC
purity = 99.2%; tR = 7.4 min.
3 - [ ( 3 (S ) - Py r ro l i d i ny l )me thoxy ] - 5 - [ ( 1S , 2R ) - 2 - ( 2 -
methoxyethyl)cyclopropyl]pyridine Trifluoroacetate (30). 1H
NMR (D2O): δ 8.23 (s, 1H), 8.16 (s, 1H), 7.75 (s, 1H), 4.28 (m, 1H),
4.20 (m, 1H), 3.58 (m, 3H), 3.46 (m, 1H), 3.38−3.23 (m, 5H), 2.96
(m, 1H), 2.30 (m, 1H), 1.96 (m, 2H), 1.69 (m, 2H), 1.27 (m, 1H),
1.13 (m, 2H). 13C NMR (D2O): δ 162.2 (TFA), 156.5, 145.9, 131.4,
127.8, 125.1, 115.8 (TFA), 71.5, 69.6, 57.3, 46.9, 45.1, 36.2, 32.2, 26.0,
21.8, 19.4, 16.1. [α]D
20 = +42.0 (c 0.70, MeOH). Anal. Calcd for
C16H24N2O2·2.0CF3COOH·1.05H2O: C, 45.9; H, 5.41; F, 21.78, N,
5.35. Found: C, 45.52; H, 5.0; F, 21.5; N, 5.31. HPLC purity = 99.4%;
tR = 7.3 min.
3-[(3(R)-Pyrrolidinyl)oxy]-5-[(1S,2R)-2-(2-methoxyethyl)-
cyclopropyl]pyridine Trifluoroacetate (31). 1H NMR (D2O): δ
8.23 (s, 1H), 8.15 (s, 1H), 7.75 (s, 1H), 5.37 (s, 1H), 3.68−3.46 (m,
6H), 3.29 (s, 3H), 2.34 (m, 2H), 1.91 (m, 1H), 1.66 (m, 2H), 1.24 (m,
1H), 1.09 (m, 2H). 13C NMR (D2O): δ 162.1 (TFA), 154.5, 146.2,
131.8, 128.7, 126.0, 115.8 (TFA), 77.2, 71.4, 57.3, 50.0, 43.4, 32.2,
29.3, 21.9, 19.4, 16.2. [α]D
20 = +34.0 (c 0.1, MeOH). Anal. Calcd for
C15H22N2O2·2.15CF3COOH·0.1H2O: C, 45.52; H, 4.82; F, 24.06; N,
5.5. Found: C, 45.38; H, 4.72; F, 24.08, N, 5.69. HPLC purity =
99.8%; tR = 6.4 min.
3-[(1-Methyl-2(S)-pyrrolidinyl)methoxy]-5-[(1R,2S)-2-(2-
methoxyethyl)cyclopropyl]pyridine Trifluoroacetate (33). 1H
NMR (D2O): δ 8.30 (s, 1H), 8.22 (s, 1H), 7.80 (s, 1H), 4.60 (dd, J =
10.8, 2.8 Hz, 1H), 4.44 (m, 1H), 3.95 (m, 1H), 3.74 (m, 1H), 3.57 (t, J
= 6.4 Hz, 2H), 3.33 (s, 3H), 3.25 (m, 1H), 3.03 (s, 3H), 2.40 (m, 1H),
2.20 (m, 1H), 2.08 (m, 2H), 1.97 (m, 1H), 1.70 (m, 2H), 1.30 (m,
1H), 1.14 (m, 2H). 13C NMR (D2O): δ 162.2 (TFA), 155.7, 146.2,
132.1, 127.9, 125.2, 115.9 (TFA), 71.5, 66.9, 66.0, 57.3, 56.8, 40.2,
32.2, 25.4, 22.0, 21.7, 19.4, 16.2. [α]D
20 = −33.8 (c 0.13, MeOH). Anal.
Calcd for C17H26N2O2·2.05CF3COOH·0.45H2O: C, 47.61; H, 5.48; F,
21.95; N, 5.26. Found: C, 47.66; H, 5.24; F, 21.73, N, 5.19. HPLC
purity = 99.8%; tR = 5.8 min.
General Procedures for Binding and Functional Studies. In
Vitro Binding Studies. [3H]Epibatidine competition studies and
broad-range screening were carried out by the National Institute of
Mental Health’s Psychoactive Drug Screening Program, contract no.
HHSN-271-2008-00025-C (NIMH PDSP). For experimental details,
please refer to the PDSP Web site http://pdsp.med.unc.edu/.
Journal of Medicinal Chemistry Article
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Cell Lines and Culture. Cell lines naturally or heterologously
expressing specific, functional, human nAChR subtypes were used.
The human clonal cell line TE671/RD naturally expresses human
muscle-type α1*-nAChRs, containing α1, β1, γ, and δ subunits, with
function detectable using 86Rb+ efflux assays.25 The human neuro-
blastoma cell line SH-SY5Y naturally expresses autonomic α3β4*-
nAChRs, containing α3, β4, probably α5, and sometimes β2 subunits,
and also displays function detectable using 86Rb+ efflux assays.26 SH-
SY5Y cells also express homopentameric α7-nAChRs. However, their
function is not detected in the 86Rb+ efflux assay under the conditions
used. SH-EP1 human epithelial cells stably transfected with human α4
and β2 subunits (SH-EP1-hα4β2 cells) have been established and the
human α4β2-nAChRs that they stably and heterologously express have
been characterized with both ion flux and radioligand binding assays.27
Details of experimental procedures used for 86Rb+ efflux assays are as
previously described.15
Also used was the recently established SH-EP1-h(α6/3)β2β3 cell
line.28 The designation (α6/3) refers to a chimeric subunit that has
amino acids from the extracellular, N-terminal, ligand-binding domain
of the human nAChR α6 subunit fused to what otherwise is the
nAChR α3 subunit. When expressed with the appropriate nAChR
subunit assembly partners, in this case, human β2 and β3 subunits,
functional nAChR are formed that have the pharmacological features
of receptors containing wild-type α6 subunits such as sensitivity to the
α6β2β3-nAChR-selective functional antagonist, α-conotoxin MII.29,30
However, levels of functional expression are much higher, enabling
assessment using assays such as 86Rb+ efflux, probably because
transmembrane and cytoplasmic domains in the nAChR α3 subunit
are more permissive for assembly and/or function of receptors than
the corresponding domains in nAChR α6 subunits. Briefly,28 wild-type
SH-EP1 cells were transfected using a cationic polymer (Qiagen,
Valencia, CA) and nAChR (α6/3), β2, and β3 subunit gene cDNAs
optimized for vertebrate expression (GeneArt, Inc., Burlingame, CA)
and delivered in different variants on the pcDNA3.1 vector
(Invitrogen, Carlsbad, CA). Following selection of triple transfectants
based on triple antibiotic resistance, clonal lines were isolated and
screened for nAChR radioligand binding capacity. Promising clones
were verified as consistently expressing a high level of functional (α6/
3)β2β3-nAChR based on 86Rb+ assays.
TE671/RD, SH-SY5Y, and transfected SH-EP1 cell lines were
maintained as low passage number (1−26 from our frozen stocks)
cultures, under continuing positive selection as appropriate, to ensure
stable expression of native or heterologously expressed nAChRs as
previously described.25 Cells were passaged once a week by splitting
just-confluent cultures 1/300 (TE671/RD), 1/10 (SH-SY5Y), or 1/
20−1/40 (transfected SH-EP1) in serum-supplemented medium to
maintain log-phase growth.
General Procedures for Behavioral Studies. Animals. BALB/cJ
male mice (8−10 weeks old at testing) were obtained from Jackson
Laboratory (Bar Harbor, ME, USA). Mice were housed four to a cage
in a colony room maintained at 22 ± 2 °C on a 12 h light−dark cycle.
All animal experiments were conducted in accordance with the NIH
Guide for the Care and Use of Laboratory Animals and the
PsychoGenics Animal Care and Use Committee.
Drugs. Compounds 24, 26, and 30 were synthesized as described
above, and sertraline was purchased from Toronto Research Chemicals
(Ontario, Canada). All compounds were dissolved in water and
administered by intraperitoneal (IP) injection or administrated orally
(PO) in a volume of 10 mL/kg.
Mouse Forced Swim Test. Procedures were based on those
previously described. Mice were individually placed into clear glass
cylinders (15 cm tall × 10 cm wide, 1 L beakers) containing 23 ± 1 °C
water 12 cm deep (approximately 800 mL). Mice were administered
vehicle, the SSRI sertraline (20 mg/kg) as a positive control, or test
compound 24, 26, or 30. Thirty minutes following IP or PO
administration (as indicated in Figure 2), mice were placed in the
water, and the time the animal spent immobile was recorded over a 6
min trial. Immobility was defined as the postural position of floating in
the water.
Statistical Analysis. Data were analyzed with Analysis of Variance
(ANOVA) with treatment group (vehicle, sertraline, or tested
compounds) as the between-group variable and total time immobile
(seconds over the 6 min trial) as the dependent variable. Significant
main effects were followed up with the post hoc Fisher’s LSD test.
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